BiologybioRxiv
Heuristic editor, no API keyVerdict: NotableMIMOSA: Guiding De Novo Antibody Design with Natural Interaction Fingerprints
De novo antibody design promises to transform therapeutic antibody and nanobody discovery.
Key numbers
- 26% hit rates on three
VerdictWorth a reader's time today.
Abstract
De novo antibody design promises to transform therapeutic antibody and nanobody discovery. Yet, success remains inconsistent across targets, with generative models often yielding no experimentally validated binders. Here we introduce MIMOSA (MIMic-Oriented Structural Antibody generation), a model-agnostic, inference-time framework that constrains diffusion-based antibody design pipelines to reproduce the interaction geometry and chemistry of a target's known cognate binder interface. Rather than searching for a productive interface from scratch, MIMOSA constrains generation around residue identities and geometries already known to support binding, while allowing the generative model to complete the surrounding antibody interface. We test MIMOSA on different interface topologies: contiguous motifs that fit within a single CDR loop and spatially dispersed hotspots distributed across the paratope. Applied without retraining to two architecturally distinct generators (RFAntibody and BoltzGen), this framework delivers experimentally validated binders-achieving sub-micromolar to single-digit nanomolar affinities-at 20-26% hit rates on three targets on which unconstrained methods produce zero or near-zero binders: KEAP1, uPA, and IL-8. By turning any target with a structurally characterised cognate binder into an accessible de novo design problem, this framework broadens the practical reach of generative antibody design to targets where unconstrained approaches currently fail.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ████░ 4 | 24% | A general-purpose tool used across several fields (Adam, ResNet, LoRA, next-generation sequencing). |
| Magnitude | ██░░░ 2 | 16% | Solid incremental gain on a meaningful problem. |
| Evidence | ███░░ 3 | 20% | Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data. |
| Novelty | ███░░ 3 | 20% | A genuinely new approach to an open problem. |
| Trajectory | ███░░ 3 | 10% | A clear path to scale. |
| Stakes | ██░░░ 2 | 10% | Benefits a professional community (practitioners, clinicians, engineers). |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we propose); breadth (many tasks, any target); novelty (alternative to status quo, discovery); verification (experimental validation); stakes (prevention or cure).
How the score was computed
- Merit
- 6.0 / 10
- Adjusted merit
- 4.9 / 10
- Attention
- 0%
- Freshness
- 87%